Last reviewed · How we verify

SCRI Development Innovations, LLC — Portfolio Competitive Intelligence Brief

SCRI Development Innovations, LLC pipeline: 2 marketed, 0 filed, 1 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 5 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
RAD001 RAD001 marketed
CVP CVP marketed Combination chemotherapy regimen Oncology
Ixabepilone (Ixempra) Ixabepilone (Ixempra) phase 3 Microtubule-stabilizing agent β-tubulin Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Alliance for Clinical Trials in Oncology · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Asan Medical Center · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Beijing Friendship Hospital · 1 shared drug class
  6. Centre Hospitalier Universitaire Dijon · 1 shared drug class
  7. Centre Hospitalier Universitaire de Besancon · 1 shared drug class
  8. Affiliated Cancer Hospital & Institute of Guangzhou Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SCRI Development Innovations, LLC:

Cite this brief

Drug Landscape (2026). SCRI Development Innovations, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scri-development-innovations-llc. Accessed 2026-06-09.

Related